Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 November 2024 | Story André Damons | Photo Supplied
Dr Emmanuel Arko-Cobbah
Dr Emmanuel Arko-Cobbah, Senior Lecturer and Medical Specialist in the Department of Surgery at the University of the Fee State (UFS) and a trauma surgeon, has recently been inducted as a Fellow of the American College of Surgeons (ACS).

Dr Emmanuel Arko-Cobbah, Senior Lecturer and Medical Specialist in the Department of Surgery at the University of the Fee State (UFS), says he hopes his induction as a fellow of the American College of Surgeons (ACS), will show the world that South Africa also produces great doctors from whom they can learn.

The ACS is dedicated to improving the care of the surgical patient and safeguarding standards of care in an optimal and ethical practice environment. Dr Arko-Cobbah was inducted on 19 October after a rigorous process. He was part of 1 800 candidates from around the world, but mostly from North America, with about 600 from other countries outside of the US and Canada.

Dr Arko-Cobbah, a trauma surgeon, says it feels surreal as it has always been his dream to become a Fellow of the American College of Surgeons, although it often felt like an impossible dream. “I truly thank God, and I am very grateful, because to me, it feels like it's all part of His plans for me, that is why He is making these things possible for me.

“As a trauma surgeon, it makes me feel I have achieved even beyond our borders, and it gives me the opportunity to also share the knowledge we have locally with the rest of the world. We have a lot to offer, but we tend to get underestimated because of where we’re from,” says Dr Arko-Cobbah.

To become a fellow of the ACS, applicants go through a selection process after applying and then they need to be nominated by three different fellows of the American College who are in good standing. If their nominations get accepted, an interview follows whereafter the reports are reviewed by the committee which then decides the outcome.

South Africa produces great doctors

According to Dr Arko-Cobbah, he hopes to put the UFS on the map with this lifelong fellowship so that the world can know South Africa also produces great doctors and that they can learn from these doctors. “The other side of the coin is for me to inspire others to also aim to get into the American College, and to dream even bigger than this. If I could do this, then anybody can. Partner with God, and dream big dreams, and make big plans. That is what I was taught by Pastor At Boshoff since I was a student, and God has always been faithful.”

After qualifying as doctor and becoming a general surgeon at the UFS, and super specialised as a trauma surgeon, Dr Arko-Cobbah completed a Surgical Leadership Programme with Harvard University in Boston, in the US. “God has always been good to me, and I am forever grateful to the support of my wife and family and continued inspiration and mentorship from Prof André Loubser. I am grateful to the late Prof Theron, and the UFS Surgery Department, past and present, for always pushing me to be better. 

News Archive

DNA sequencer launched at the UFS
2013-11-25

Dr Gansen Pillay, Deputy Chief Executive Officer of the National Research Foundation, explaining to the scholars what will be expected of them.

The University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus.

The DNA sequencer will allow the Free State province to produce viral and bacterial genetic data to fight the local development of HIV/ Aids and TB drug resistance.

The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world, with over 2 million patients on treatment. However, these successful treatment programmes are now being threatened by the appearance of drug resistance.

The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2 000 medical officers in the treatment of drug resistance strains.

The Department of Medical Microbiology and Virology in the Medical School at the UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV and TB drug-resistance results. This new machine will enable cutting-edge research to take place, using the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques.

“HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients appropriately who fail treatment, and use the results to cost-effectively extend and improve patients’ lives,” says Dr Cloete van Vuuren, Specialist in Infectious Diseases at the UFS’s Faculty of Health.

Dr Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at the UFS, adds: “We have been looking forward to expanding our work with the clinicians and researchers, using DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept